US FDA approves new indication for Epidiolex (cannabidiol;CBD) oral solution to treat seizures associated with tuberous sclerosis complex

Approval is for use in patients aged ≥ 1year with this rare genetic disease that causes benign tumours and usually affects CNS. It was previously approved only for seizures linked to two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome (as in UK).


US Food and Drug Administration